TD Cowen lowered the firm’s price target on Amwell (AMWL) to $7 from $10 and keeps a Hold rating on the shares. The firm said its 3Q adj. EBITDA beat/raise and reiterating ’26 CF breakeven target are positive for cost reduction priorities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell price target lowered to $6 from $8 at Stifel
- American Well: Balancing Cost Reductions and Revenue Challenges Amidst Transformation
- Amwell Reports Strong Q3 2025 Financial Performance
- American Well: Hold Rating Amid Revenue Concerns and Strategic Initiatives
- Amwell lowers top-end of FY25 revenue view to $245M-$248M from $245M-$250M